An investigation into the antidyskinetic and reinforcing effects of UWA-101 in Sprague Dawley rats

Angela McLelland

Research output: ThesisDoctoral Thesis

98 Downloads (Pure)

Abstract

While L-DOPA is the gold-standard treatment for Parkinson's disease, side effects called dyskinesias can develop after long-term treatment. This thesis validated that a novel drug called UWA-101 reduces L-DOPA-induced dyskinesias in the reserpine rat model of Parkinson's disease and expanded upon this model as an inexpensive and rapid screening tool for other antidyskinetic drugs compared to more time-consuming and expensive animal models. For the first time, it was demonstrated that UWA-101 lacks the subjective effects of its parent compound MOMA ("ecstasy") and, with its antidyskinetic effects, may be an effective treatment for dyskinesias in Parkinson's disease.
Original languageEnglish
QualificationDoctor of Philosophy
Awarding Institution
  • The University of Western Australia
Thesis sponsors
Award date14 Feb 2020
DOIs
Publication statusUnpublished - 2020

Fingerprint Dive into the research topics of 'An investigation into the antidyskinetic and reinforcing effects of UWA-101 in Sprague Dawley rats'. Together they form a unique fingerprint.

  • Cite this